| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1011515393 |
| P356 | DOI | 10.1186/S12879-015-1153-Z |
| P932 | PMC publication ID | 4604622 |
| P698 | PubMed publication ID | 26464143 |
| P2093 | author name string | Jin Han Kang | |
| Sung Chul Lee | |||
| Soo Young Lee | |||
| Seung Beom Han | |||
| Dae Chul Jeong | |||
| P2860 | cites work | Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. | Q51784460 |
| Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan | Q80636664 | ||
| Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children | Q83240517 | ||
| Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children | Q84772825 | ||
| Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis | Q27002495 | ||
| Extended-spectrum beta-lactamases and clinical outcomes: current data | Q33236875 | ||
| Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. | Q34108527 | ||
| Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study | Q34285984 | ||
| Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-β-lactamase-producing Escherichia coli. | Q34597721 | ||
| Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment | Q35056715 | ||
| Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms | Q36364199 | ||
| Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern | Q37091253 | ||
| Outcome of Antimicrobial Therapy of Pediatric Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae | Q37518263 | ||
| The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae | Q38058927 | ||
| Aminoglycosides: how should we use them in the 21st century? | Q38154113 | ||
| Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. | Q38280656 | ||
| Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella | Q39477943 | ||
| Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection | Q40271482 | ||
| Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months | Q40313997 | ||
| Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children | Q40433501 | ||
| High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. | Q42054872 | ||
| The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. | Q42210504 | ||
| Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children | Q42256010 | ||
| Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study | Q43540067 | ||
| Urinary tract infections caused by extended-spectrum betalactamase-producing bacteria in children: a matched casecontrol study | Q43743638 | ||
| Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients | Q44054169 | ||
| Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases | Q44706480 | ||
| Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases | Q46956002 | ||
| P921 | main subject | Escherichia coli | Q25419 |
| Klebsiella pneumoniae | Q132592 | ||
| urinary tract infection | Q221668 | ||
| P304 | page(s) | 414 | |
| P577 | publication date | 2015-10-13 | |
| P1433 | published in | BMC Infectious Diseases | Q15759919 |
| P1476 | title | Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae | |
| P478 | volume | 15 |
| Q37405155 | A new assay for the simultaneous identification and differentiation of Klebsiella oxytoca strains |
| Q38985815 | Antibiotic Resistance in Pediatric Urinary Tract Infections |
| Q94063574 | Antimicrobial Pharmacotherapy Management of Urinary Tract Infections in Pediatric Patients |
| Q36298715 | Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014 |
| Q93145205 | Available evidence of antibiotic resistance from extended-spectrum β-lactamase-producing Enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis |
| Q37218571 | Diagnosis of Urinary Tract Infections in Children. |
| Q59336583 | Differentiating Kawasaki disease from urinary tract infection in febrile children with pyuria and C-reactive protein elevation |
| Q33668402 | ESBL Production Among E. coli and Klebsiella spp. Causing Urinary Tract Infection: A Hospital Based Study |
| Q41987129 | Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort |
| Q64955622 | Failure of Ciprofloxacin Therapy in the Treatment of Community-Acquired Acute Pyelonephritis caused by In-Vitro Susceptible Escherichia coli Strain Producing CTX-Type Extended-Spectrum β-Lactamase. |
| Q48165659 | Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study. |
| Q49548296 | Frequency of Multidrug-Resistant Organisms Cultured From Urine of Children Undergoing Clean Intermittent Catheterization |
| Q37579184 | High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal. |
| Q92717672 | Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole |
| Q47595207 | Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children |
| Q54250219 | Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. |
| Q33776486 | Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli |
| Q92898544 | Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children |
Search more.